MYGN Myriad Genetics, Inc.
Stock · NasdaqGS · United States · Healthcare · US62855J1043
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Myriad Genetics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
5.92 USD
-5.88%
52-week range
2.74 – 8.09
Dividend yield—
Market cap601.6M
NowoTrade score
15 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:06. Information, not advice.
Results
Next results
23 Feb 2027
in 108 days · 16:00 · estimate -0.18
Last results
-0.11 vs -0.20 estimated
04 Nov 2026 · Beat +44.9%
Beat the estimate
9 of 12
2 missed · 1 in line
Average surprise
+161.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 23 Feb 2027 16:00 | -0.18 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.20 | -0.11 | +44.9% | Beat |
| 30 Jul 2026 16:00 | -0.06 | -0.25 | -332.7% | Miss |
| 05 May 2026 16:00 | -0.07 | -0.09 | -34.7% | Miss |
| 23 Feb 2026 16:00 | -0.02 | 0.04 | +348.3% | Beat |
| 03 Nov 2025 16:00 | -0.01 | — | +100.0% | — |
| 05 Aug 2025 16:00 | -0.01 | 0.05 | +724.2% | Beat |
| 06 May 2025 16:00 | -0.05 | -0.03 | +44.8% | Beat |
| 24 Feb 2025 16:00 | 0.03 | 0.03 | -0.9% | In line |
| 07 Nov 2024 16:00 | 0.02 | 0.06 | +211.0% | Beat |
| 06 Aug 2024 16:00 | -0.01 | 0.05 | +561.7% | Beat |
| 07 May 2024 16:00 | -0.11 | -0.01 | +91.1% | Beat |
| 27 Feb 2024 16:00 | 0.01 | 0.04 | +214.2% | Beat |
| 06 Nov 2023 16:00 | -0.08 | -0.03 | +63.6% | Beat |
| 02 Aug 2023 20:00 | -0.09 | -0.08 | +7.3% | Beat |
| 03 May 2023 16:00 | -0.19 | -0.21 | -8.4% | Miss |
| 28 Feb 2023 16:00 | -0.17 | -0.12 | +30.4% | Beat |
| 01 Nov 2022 09:00 | -0.08 | -0.19 | -141.3% | Miss |
| 04 Aug 2022 07:00 | 0.02 | 0.04 | +84.6% | Beat |
| 05 May 2022 09:00 | -0.09 | -0.03 | +65.6% | Beat |
| 24 Feb 2022 09:00 | -0.06 | -0.02 | +64.1% | Beat |
| 02 Nov 2021 08:00 | -0.01 | -0.02 | -100.0% | Miss |
| 03 Aug 2021 07:00 | -0.10 | 0.12 | +214.3% | Beat |
| 03 May 2021 16:00 | -0.15 | -0.06 | +59.1% | Beat |
| 23 Feb 2021 16:00 | -0.23 | -0.12 | +47.8% | Beat |
| 05 May 2020 17:00 | 0.01 | -0.08 | -1,166.7% | Miss |
| 06 Feb 2020 16:00 | 0.29 | 0.23 | -21.7% | Miss |
| 04 Nov 2019 16:00 | 0.31 | 0.08 | -74.5% | Miss |
| 13 Aug 2019 16:00 | 0.48 | 0.41 | -14.6% | Miss |
| 07 May 2019 16:00 | 0.43 | 0.46 | +6.3% | Beat |
| 05 Feb 2019 16:00 | 0.39 | 0.38 | -3.1% | Miss |
| 06 Nov 2018 16:00 | 0.31 | 0.43 | +38.2% | Beat |
| 21 Aug 2018 16:00 | 0.33 | 0.38 | +15.5% | Beat |
| 08 May 2018 06:00 | 0.27 | 0.31 | +13.9% | Beat |
| 06 Feb 2018 16:00 | 0.24 | 0.31 | +30.9% | Beat |
| 07 Nov 2017 16:00 | 0.21 | 0.26 | +26.4% | Beat |
| 08 Aug 2017 16:00 | 0.26 | 0.30 | +13.2% | Beat |
| 02 May 2017 16:00 | 0.24 | 0.27 | +13.3% | Beat |
| 07 Feb 2017 16:00 | 0.24 | 0.26 | +8.2% | Beat |
| 01 Nov 2016 16:00 | 0.25 | 0.23 | -9.3% | Miss |
| 09 Aug 2016 16:00 | 0.37 | 0.32 | -14.4% | Miss |
| 03 May 2016 16:00 | 0.38 | 0.41 | +7.8% | Beat |
| 02 Feb 2016 16:00 | 0.41 | 0.45 | +10.1% | Beat |
| 03 Nov 2015 16:00 | 0.35 | 0.41 | +16.3% | Beat |
| 11 Aug 2015 16:00 | 0.41 | 0.41 | -0.4% | In line |
| 05 May 2015 16:00 | 0.39 | 0.40 | +1.4% | Beat |
| 03 Feb 2015 16:00 | 0.34 | 0.40 | +16.0% | Beat |
| 04 Nov 2014 16:00 | 0.27 | 0.25 | -6.5% | Miss |
| 12 Aug 2014 16:00 | 0.46 | 0.48 | +3.7% | Beat |
| 06 May 2014 16:00 | 0.45 | 0.60 | +32.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 824.5M | -1.6% | -365.9M | -44.4% | -3.95 | -180.1% | -25.6M |
| 2024 | 837.6M | +11.2% | -127.3M | -15.2% | -1.41 | +55.7% | -38.4M |
| 2023 | 753.2M | +11.0% | -263.3M | -35.0% | -3.18 | -128.8% | -184.2M |
| 2022 | 678.4M | — | -112M | -16.5% | -1.39 | — | -151.6M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 15 Dec 2023 | 21.48 | 21.60 | 20.19 | 20.74 | -2.40% | 3,058,500 | |
| 14 Dec 2023 | 21.40 | 22.16 | 20.98 | 21.25 | +1.77% | 856,500 | |
| 13 Dec 2023 | 19.68 | 20.92 | 19.23 | 20.88 | +9.61% | 951,800 | |
| 12 Dec 2023 | 19.12 | 19.35 | 18.76 | 19.05 | 0.00% | 581,900 | |
| 11 Dec 2023 | 18.41 | 19.07 | 17.80 | 19.05 | +2.86% | 752,100 | |
| 08 Dec 2023 | 18.23 | 19.02 | 17.86 | 18.52 | +0.65% | 464,800 | |
| 07 Dec 2023 | 17.98 | 18.44 | 17.80 | 18.40 | +2.34% | 563,800 | |
| 06 Dec 2023 | 18.40 | 18.57 | 17.95 | 17.98 | -1.69% | 470,500 | |
| 05 Dec 2023 | 18.37 | 18.62 | 18.10 | 18.29 | -1.72% | 499,800 | |
| 04 Dec 2023 | 18.78 | 19.03 | 18.32 | 18.61 | -3.22% | 696,800 | |
| 01 Dec 2023 | 19.16 | 19.29 | 18.61 | 19.23 | +0.73% | 571,700 | |
| 30 Nov 2023 | 19.55 | 19.67 | 18.98 | 19.09 | -0.78% | 524,800 | |
| 29 Nov 2023 | 18.80 | 19.88 | 18.80 | 19.24 | +3.00% | 744,000 | |
| 28 Nov 2023 | 18.00 | 18.95 | 17.77 | 18.68 | +3.72% | 734,500 | |
| 27 Nov 2023 | 17.92 | 18.18 | 17.53 | 18.01 | -0.06% | 732,200 | |
| 24 Nov 2023 | 17.73 | 18.04 | 17.52 | 18.02 | +1.81% | 204,500 | |
| 22 Nov 2023 | 17.76 | 17.89 | 17.54 | 17.70 | +1.26% | 493,600 | |
| 21 Nov 2023 | 17.82 | 17.99 | 17.46 | 17.48 | -3.21% | 494,300 | |
| 20 Nov 2023 | 18.00 | 18.28 | 17.71 | 18.06 | +1.06% | 501,300 | |
| 17 Nov 2023 | 17.43 | 17.89 | 16.80 | 17.87 | +3.83% | 867,800 | |
| 16 Nov 2023 | 17.40 | 17.57 | 16.79 | 17.21 | -1.21% | 622,300 | |
| 15 Nov 2023 | 16.61 | 17.76 | 16.61 | 17.42 | +3.63% | 582,700 | |
| 14 Nov 2023 | 17.07 | 17.31 | 16.63 | 16.81 | +1.94% | 969,700 | |
| 13 Nov 2023 | 16.34 | 16.68 | 16.10 | 16.49 | +0.24% | 1,009,400 | |
| 10 Nov 2023 | 16.27 | 16.73 | 16.00 | 16.45 | +0.98% | 1,133,800 |
Page 30 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 18:50
- TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75 (opens in a new tab) Benzinga · 05 Nov 2026 16:28
- Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8 (opens in a new tab) Benzinga · 05 Nov 2026 15:56
- Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 11:04
- Myriad Genetics Detects Unauthorized Access In It Network On Nov. 2; Temporarily Suspended Testing Operations, Order Management Systems Due To Incident; Probing Potential Access To Patient Records (opens in a new tab) Benzinga · 05 Nov 2026 10:16
- Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised as ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 09:13
- Myriad Genetics (NASDAQ:MYGN) Q3 Beats Estimates, Raises Guidance, and Strikes Prenatal Sale to Labcorp (opens in a new tab) ChartMill · 05 Nov 2026 00:25
- Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 04 Nov 2026 23:45
- Myriad: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 04 Nov 2026 23:17
- Myriad Genetics Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 04 Nov 2026 23:14
- Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7% (opens in a new tab) StockStory · 04 Nov 2026 21:34
- Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives (opens in a new tab) 04 Nov 2026 21:05
- Myriad Genetics Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 04 Nov 2026 18:26
- Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est (opens in a new tab) Benzinga · 04 Nov 2026 17:36
- Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:07
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 6.29 USD
- Market cap
- 601.6M
- Last dividend
- 1.7500 USD · 01 Jul 2009
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 01 Jul 2009 | 1.7500 USD |
| 15 Jun 2009 | 1.7500 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 11.2 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 6.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.3 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 0.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -6.5× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -10.06× | Weak | 14.98× |
| Price / book | 2.11× | Fair | 3.87× |
| Price / sales | 0.71× | Good | 3.42× |
| EV / EBITDA | -12.08× | Weak | 13.22× |
| Free cash flow yield | 0.6% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 68.3% | Good | 59.2% |
| Operating margin | -19.5% | Weak | 7.8% |
| Net margin | -16.1% | Weak | 3.4% |
| Return on equity | -40.2% | Weak | 5.9% |
| Return on assets | -10% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 6.7% | Fair | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.78× | Good | 0.46× |
| Interest cover | -6.46× | Weak | 3.26× |
| Current ratio | 1.98× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow MYGN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.